JP2011523857A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011523857A5 JP2011523857A5 JP2011513010A JP2011513010A JP2011523857A5 JP 2011523857 A5 JP2011523857 A5 JP 2011523857A5 JP 2011513010 A JP2011513010 A JP 2011513010A JP 2011513010 A JP2011513010 A JP 2011513010A JP 2011523857 A5 JP2011523857 A5 JP 2011523857A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- complex
- apoa
- polynucleotide
- gene construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 claims 11
- 108091033319 polynucleotide Proteins 0.000 claims 11
- 239000002157 polynucleotide Substances 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 108010027004 Apolipoproteins A Proteins 0.000 claims 5
- 102000018619 Apolipoproteins A Human genes 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 claims 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 2
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 208000005452 Acute intermittent porphyria Diseases 0.000 claims 1
- -1 ApoA-III Proteins 0.000 claims 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 1
- 108010087614 Apolipoprotein A-II Proteins 0.000 claims 1
- 102000009081 Apolipoprotein A-II Human genes 0.000 claims 1
- 102100037320 Apolipoprotein A-IV Human genes 0.000 claims 1
- 108010061118 Apolipoprotein A-V Proteins 0.000 claims 1
- 102000011936 Apolipoprotein A-V Human genes 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims 1
- 208000006154 Chronic hepatitis C Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101000959789 Mus musculus Interferon alpha-1 Proteins 0.000 claims 1
- 101000959702 Mus musculus Interferon alpha-5 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 206010036182 Porphyria acute Diseases 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 208000010710 hepatitis C virus infection Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001012 protector Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ESP200801796 | 2008-06-13 | ||
| ES200801796 | 2008-06-13 | ||
| PCT/ES2009/070224 WO2009150284A2 (es) | 2008-06-13 | 2009-06-12 | Conjugados de apo-a para la administración de compuestos biológicamente activos |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208266A Division JP2015038124A (ja) | 2008-06-13 | 2014-10-09 | 生物学的活性を有する化合物の投与のための複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011523857A JP2011523857A (ja) | 2011-08-25 |
| JP2011523857A5 true JP2011523857A5 (https=) | 2012-07-19 |
| JP5685529B2 JP5685529B2 (ja) | 2015-03-18 |
Family
ID=41338617
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513010A Expired - Fee Related JP5685529B2 (ja) | 2008-06-13 | 2009-06-12 | 生物学的活性を有する化合物の投与のための複合体 |
| JP2014208266A Pending JP2015038124A (ja) | 2008-06-13 | 2014-10-09 | 生物学的活性を有する化合物の投与のための複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014208266A Pending JP2015038124A (ja) | 2008-06-13 | 2014-10-09 | 生物学的活性を有する化合物の投与のための複合体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20110293557A1 (https=) |
| EP (1) | EP2305309A2 (https=) |
| JP (2) | JP5685529B2 (https=) |
| CN (1) | CN102123737B (https=) |
| AU (1) | AU2009256547B2 (https=) |
| BR (1) | BRPI0915093A2 (https=) |
| CA (1) | CA2727811A1 (https=) |
| MX (1) | MX2010013759A (https=) |
| RU (1) | RU2567667C2 (https=) |
| WO (1) | WO2009150284A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2347627B1 (es) * | 2009-03-06 | 2011-10-10 | Isdin, S.A. | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. |
| AU2010329805B2 (en) | 2009-12-11 | 2016-07-14 | Proyecto De Biomedicina Cima S.L. | New conjugates and compositions for immunotherapy and anti-tumoral treatment |
| US20120308517A1 (en) | 2010-02-09 | 2012-12-06 | Digna Biotech, S.L. | Compositions for the treatment of infectious and tumoural diseases |
| CA2802388A1 (en) * | 2010-06-15 | 2011-12-22 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer |
| EP2673296B1 (en) | 2011-02-07 | 2018-10-24 | Cerenis Therapeutics Holding SA | Lipoprotein complexes and manufacturing and uses thereof |
| JP2014132832A (ja) * | 2011-05-10 | 2014-07-24 | Sekisui Chem Co Ltd | 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体 |
| BR112013033562A2 (pt) * | 2011-08-25 | 2017-02-14 | Hoffmann La Roche | proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas |
| CN103073646A (zh) * | 2012-03-13 | 2013-05-01 | 华中科技大学 | 一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用 |
| ES2427854B1 (es) * | 2012-03-29 | 2014-09-15 | Universidad De Valladolid | Sensores de calcio y métodos para la detección de calcio libre intracelular |
| EP2735874A1 (en) | 2012-11-21 | 2014-05-28 | Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro | Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer |
| EP3004160B1 (en) * | 2013-06-05 | 2022-12-28 | CSL Limited | Process for preparing apolipoprotein a-i (apo a-i) |
| KR101656929B1 (ko) * | 2014-06-02 | 2016-09-13 | 씨제이제일제당 (주) | 반추동물의 메탄 생성 저감용 사료 첨가제 조성물 |
| GB201410507D0 (en) * | 2014-06-12 | 2014-07-30 | Univ Bath | Drug delivery enhancement agents |
| WO2017044424A1 (en) | 2015-09-08 | 2017-03-16 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
| US11390854B2 (en) | 2017-05-09 | 2022-07-19 | Fundacion Para La Investigacion Medica Aplicada | Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof |
| JP7791715B2 (ja) * | 2019-04-05 | 2025-12-24 | 韓國セラミック技術院 | Ｃｓｑ－タグを用いたタンパク質の発現及び精製方法 |
| CN110483648A (zh) * | 2019-08-27 | 2019-11-22 | 南京安吉生物科技有限公司 | 一种融合多肽及其应用 |
| FR3100715B1 (fr) * | 2019-09-12 | 2023-09-29 | Francais Du Sang Ets | Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0238645A1 (en) * | 1985-10-03 | 1987-09-30 | Biotechnology Research Partners, Ltd. | Novel lipoprotein-based drug-delivery systems |
| EP0239631A4 (en) | 1985-10-04 | 1989-01-12 | Biotech Res Partners Ltd | RECOMBINANT APOLIPOPROTEINS AND METHODS. |
| US5643757A (en) | 1994-03-21 | 1997-07-01 | American Cyanamid Company | High yield production of human apolipoprotein A1 in E. coli. |
| US5766582A (en) | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| EP0934337B1 (en) | 1996-08-23 | 2007-12-19 | Esperion Therapeutics Inc. | A process for purifying apolipoprotein a or apolipoprotein e from human plasma |
| CA2277199A1 (en) | 1996-09-11 | 1998-03-19 | Hans Ageland | A process for purifying apolipoproteins and a composition for use in the process |
| US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| ES2146552B1 (es) | 1998-11-24 | 2001-04-16 | Inst Cientifico Tecnol Navarra | Peptidos inhibidores de tgf/31 |
| US6809186B1 (en) | 1999-01-22 | 2004-10-26 | Martek Biosciences Corporation | Simple method for labeled conjugate production |
| EP1276754A4 (en) * | 2000-04-14 | 2005-04-06 | Nuvelo Inc | Materials and methods relating to lipid metabolism |
| AU2008201887B2 (en) * | 2000-11-10 | 2011-06-30 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
| CN1520259A (zh) | 2001-04-25 | 2004-08-11 | ���ݴ�ѧУ��ίԱ�� | 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法 |
| US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
| WO2004041179A2 (en) * | 2002-10-30 | 2004-05-21 | The United States Of America As Represented By The Secretary Of Health And Human Services, Nih | Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation |
| EP1572242B1 (en) | 2002-12-13 | 2014-04-16 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| EP2314285B2 (en) | 2003-02-14 | 2019-09-18 | Children's Hospital & Research Center at Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| JP2004277355A (ja) | 2003-03-17 | 2004-10-07 | Beacle Inc | 血友病治療用薬剤及びそれを用いた血友病治療方法 |
| ES2304069B1 (es) | 2003-08-22 | 2009-08-12 | Proyecto De Biomedicina Cima, S.L. | Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1). |
| US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US20050255042A1 (en) | 2003-11-24 | 2005-11-17 | The Regents Of The University Of California Office Of Technology Transfer, University Of California | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy |
| US8097283B2 (en) * | 2004-01-15 | 2012-01-17 | Mount Sinai School Of Medicine | Methods and compositions for imaging |
| CN1922313B (zh) * | 2004-02-10 | 2011-10-26 | 生物马林医药公司 | 酸性α-糖苷酶及其片段 |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
| WO2006135436A2 (en) | 2004-10-22 | 2006-12-21 | University Of Florida Research Foundation, Inc. | Inhibition of gene expression and therapeutic uses thereof |
| EP1874824A4 (en) | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
| MX2008001865A (es) | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
| AU2006282722A1 (en) | 2005-08-26 | 2007-03-01 | Cerenis Therapeutics Holdings S.A. | Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria |
| CA2607056C (en) | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| WO2007048857A1 (es) | 2005-10-24 | 2007-05-03 | Proyecto De Biomedicina Cima, S.L. | USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE |
| EP1969000A2 (en) | 2005-12-06 | 2008-09-17 | Centre National de la Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US20090238883A1 (en) | 2006-04-28 | 2009-09-24 | Kren Betsy T | Liver-specific nanocapsules and methods of using |
| US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
| EP2049560B1 (en) * | 2006-07-13 | 2013-05-15 | Novozymes Biopharma DK A/S | Process for preparing particles of proteinaceous material |
| KR100817024B1 (ko) * | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
| US20090110739A1 (en) * | 2007-05-15 | 2009-04-30 | University Of North Texas Health Science Center At Forth Worth | Targeted cancer chemotherapy using synthetic nanoparticles |
| WO2009036460A2 (en) * | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
-
2009
- 2009-06-12 EP EP09761841A patent/EP2305309A2/en not_active Withdrawn
- 2009-06-12 US US12/997,829 patent/US20110293557A1/en not_active Abandoned
- 2009-06-12 BR BRPI0915093A patent/BRPI0915093A2/pt not_active Application Discontinuation
- 2009-06-12 CA CA2727811A patent/CA2727811A1/en not_active Abandoned
- 2009-06-12 JP JP2011513010A patent/JP5685529B2/ja not_active Expired - Fee Related
- 2009-06-12 MX MX2010013759A patent/MX2010013759A/es active IP Right Grant
- 2009-06-12 AU AU2009256547A patent/AU2009256547B2/en not_active Ceased
- 2009-06-12 CN CN200980131382.9A patent/CN102123737B/zh not_active Expired - Fee Related
- 2009-06-12 WO PCT/ES2009/070224 patent/WO2009150284A2/es not_active Ceased
- 2009-06-12 RU RU2011100801/10A patent/RU2567667C2/ru not_active IP Right Cessation
-
2014
- 2014-10-09 JP JP2014208266A patent/JP2015038124A/ja active Pending
-
2015
- 2015-11-20 US US14/947,164 patent/US20160074475A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523857A5 (https=) | ||
| RU2011100801A (ru) | Конъюгаты для введения биологически активных соединений | |
| FI3642340T3 (fi) | Muunneltu l-asparaginaasi | |
| JP2020023567A5 (https=) | ||
| JP2020531032A5 (https=) | ||
| JP2010500399A5 (https=) | ||
| JP2006512300A5 (https=) | ||
| JP2009292810A5 (https=) | ||
| JP2013513377A5 (https=) | ||
| JP2010515686A5 (https=) | ||
| JP2008530245A5 (https=) | ||
| JP2013172743A5 (https=) | ||
| JP2014500868A (ja) | 癌及び慢性感染の治療のための作動薬活性を有するｉｌ−２由来のポリペプチド | |
| HRP20191852T1 (hr) | Polipeptidi | |
| JP2012500001A5 (https=) | ||
| JP2017529326A5 (https=) | ||
| JP2019534884A5 (https=) | ||
| AU2009275135A1 (en) | Angiopoietin derived peptides | |
| CA2765188A1 (en) | Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer | |
| WO2004016643A3 (en) | Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines | |
| HRP20161458T1 (hr) | Polipeptidi, polinukleotidi i pripravci namijenjeni upotrebi u liječenju latentne tuberkuloze | |
| JP2009112314A5 (https=) | ||
| JP2016506413A5 (https=) | ||
| TW200526780A (en) | TNF antagonists and TNF inhibitors comprising the same as the active ingredient | |
| JP2018521977A5 (https=) |